2018 annual scientific session saturday handouts€¦ · 2018 annual scientific session saturday...
TRANSCRIPT
2018 ANNUAL SCIENTIFIC SESSION Saturday Handouts
February 23-24, 2018 • Grandover Resort • Greensboro, NCThis continuing medical education activity is sponsored by the American College of Physicians
1
MSK examination skills
ACP North Carolina Chapter
Claudia L Campos, MD, FACP
1
2
In one word could you describe how you feel?
• Text CLAUDIACAMPO786 to 22333
3
2
4
lower backshoulder
knee
5
Systematic approach to patients with MSK complaints
6
3
Lower Back Pain Facts
70% of acute LBP are due to muscle strain or sprain
Most resolve after 2 weeks
> 6 months of sick leave 50% return to work
10% develop chronic lower back pain
Peak between ages 35 and 55
Acute back pain less than 4 weeks, subacute 4 to 12 weeks, and chronic more than 12 weeks
7
Lower Back Pain Facts
Estimated to affect 8 out of 10 Americans at some point in their lives
Main reason for missed days at work
Second most common reason for doctor's visits
Estimated 75% to 90% of patients back pain disappears spontaneously within four to six weeks
8
Non spinal causes of back pain
Back/buttocks/leg pain
Hip OAPiriformis syndromeIschial bursitisSacroiliac joint dysfunction/sacroiliitisRadiculitis/ radiculopathyMyofascial pain
Common innervation
https:/Wikipedia9
4
The 3 minute Lower back Physical Exam
10
Spinous process tenderness?
Red flags associated with the highest post‐test probability of a vertebral fracture:
Older age
Prolonged use of corticosteroids
Severe trauma
Presence of contusion or abrasion
Downie A et al. Red flags to screen for malignancy and fracture in patients with low back pain: systematic review. BMJ 2013;347:f7095
11
Hip Osteoarthritis: pain patterns
Groin
Buttock‐back
Anterior thigh
Posterior thigh
Anterior knee
Shin and calf
Khan NQ et al .Hip osteoarthritis: where is the pain?
Ann R Coll Surg Engl 2004;86:119–21.
12
5
Piriformis Syndrome
Special tests
Pain with palpation of the sciatic notchFAIR: Flexion Adduction Internal Rotation
Piriformis sign
• By Patrick J. Lynch & KDS4444 ‐https://commons.wikimedia.org/wiki/File:Skeleton_whole_body_ant_lat_views.svg, CC BY‐SA 2.5, https://commons.wikimedia.org/w/index.php?curid=53169641
13
Sacroiliac joint pain
14
Rotator cuff evaluation
15
6
16
17
Clinical features
Aching pain in the top of the shoulder, lateral aspect of the upper arm, and deltoid insertion
Pain with movement particularly abduction and internal rotation
Night pain when rolling onto the affected side
Restriction of shoulder movements and weaknesslifting, or reaching behind
18
7
Shoulder Anatomy: anterior view
http://www.investinlibya.org/analyzing‐anatomy‐of‐the‐shoulder‐and‐arm/19
Shoulder Anatomy: posterior view
http://www.investinlibya.org/analyzing‐anatomy‐of‐the‐shoulder‐and‐arm/20
Rotator cuff pathology
21
8
22
Among pain provocation tests, a positive painful arc test result was the only finding with a positive LR greater than 2.0 for RCD (3.7 [95% CI, 1.9‐7.0]), and a normal painful arc test result had the lowest negative LR (0.36 [95% CI, 0.23‐0.54]).
Hermans J et al. SMA: Does this patient with shoulder pain have rotator cuff disease? The Rational Clinical Examination systematic review. JAMA. 2013, 310: 837‐847. 10.1001/jama.2013.276187.
23
Practice time: painful arc test
24
9
Testing for Rotator cuff tear
Drop arm test External rotation lag test
Sensitivity (%) 10–73 46–98
Specificity(%) 77–98 72–98
LR and Confidence Interval CI
3.3; 95% [CI], 1.0 to 11 7.2; 95% [CI], 1.7 to 31
25
Practice time: External Rotation Lag Test
26
27
10
Meniscus tears
28
Meniscus tears
• More common in men than in women 2.5:1 to 4:1.• Most common activities: cutting or pivoting (iesoccer, basketball, wrestling, football, gymnastics, and skiing)
• Medial meniscal tears are more common than lateral meniscal tears
• Incidence peaks in men in the third decade• In women, incidence remains constant beginning in the second decade
• <30 years: single traumatic event• >30 years:degenerative tears become more common
29
Meniscus: special tests
Smith BE, Thacker D, Crewesmith A, et al. Special tests for assessing meniscal tears within the knee: a systematic review and meta‐analysisBMJ Evidence‐Based Medicine 2015;20:88‐97 30
11
A ‘mechanical’ block to a full range of movement or a ‘mechanically’ unstable knee would usually indicate an MRI and a surgical opinion.
31
Is arthroscopic surgery beneficial in treating non-traumatic, degenerative medial meniscal tears? A five
year follow-up
32
Surgery vs PT for a Meniscal Tear andOsteoarthritis
WOMAC 20.9 vs. 18.5
Katz et al N Engl J Med. 2013 May 2; 368(18): 1675–1684
33
12
Do you want to practice the Thesallytest?
34
Thank you!
35
references
• Hermans J et al. Does This Patient With Shoulder Pain Have Rotator Cuff Disease? The Rational Clinical Examination Systematic Review. JAMA. 2013;310(8):837‐847. doi:10.1001/jama.2013.276187.
• Hegedus EJ Shoulder examination ; Systematic review. Br J Sports Med 2008;42:80‐92 doi:10.1136/bjsm.2007
• Johnson MAJ, et al Acute Knee Effusions: A Systematic Approach to Diagnosis. Am FamPhysician. 2000 Apr 15;61(8):2391‐2400.
• Katz et al. Surgery vs PT for a Meniscal Tear and Osteoarthritis. N Engl J Med. 2013 May 2; 368(18): 1675–1684
• Herrlin et al. Is arthroscopic surgery beneficial in treating non‐traumatic, degenerative medial meniscal tears? A five year follow‐up. Knee Surg Sports Traumatol Arthrosc (2013) 21:358–364
• McHale K.J. et al. Physical examination of meniscus tears. The meniscus. Springer. 2010
• Smith BE, et al. Special tests for assessing meniscal tears within the knee: a systematic review and meta‐analysis. BMJ Evidence‐Based Medicine 2015;20:88‐97.
36
13
Injection supplies for large joints
• Medications: 1 cc triamcinolone 40 mg/cc2cc lidocaine 1 or 2 %
• Syringes: 3 cc for injections10 cc for arthrocenthesis
• Needles: 25 Gauge 1.5 Inch for injections20 Gauge 1.5 Inch for injections
• Clean with betadine or chlorprep• Bandaid• Gloves
37
1
SYSTEMATIC APPROACH TO EKG
1
Systematic Approach to ECGAdopt a systematic approach to ECG assessment
• Rate• Rhythm• Axis• P wave and PR interval• QRS• ST segment• T wave• QT interval• Additional waves
Bundle of His
http://www.yorkheart.com/Patient‐Heart‐Education/how‐your‐heart‐works.aspx2
3
2
4
5
6
3
7
8
9
4
10
11
12
5
13
14
15
6
16
17
18
7
19
20
21
8
22
23
24
9
25
26
27
10
28
29
30
11
31
1
CODE BLUE/ Management of Common Unstable Scenarios Encountered during Residency
PJ Miller, MD
Wake Forest Baptist Medical Center
Who we are:
PJ Miller, MD
Combined Internal Medicine/Pediatrics
Hematology
Critical Care Medicine
2
Crystal M. Anderson, RN, BSN, CEN, SANE
Wake Forest Baptist Medical Center
Conflicts of Interest
• I have no conflicts of interest to report
3
2
Wake Forest Baptist Medical Center
Goals and Objectives (Yours)
• To better understand common pitfalls of running a code and how to avoid them
• To learn styles of effective communication
• To learn how to establish control for effective teamwork
• To have fun
• To have a group discussion where we all teach and all can learn
4
Wake Forest Baptist Medical Center
Goals and Objectives (Mine)• To lead and engage a discussion on “how” to run a code
• To offer skills and insight that you can incorporate into your own style
• NOT to read overly detailed slides that you’ll forget
• To use humor and poorly timed jokes as a learning process
• To have fun
5
Overview of BLS and ACLSCrystal Anderson, BSN, RN, CEN, SANE
3
Wake Forest Baptist Medical Center
You found a dead guy… Now what?
• Call for HELP!!• You cannot code someone alone…
• Begin chest compressions until help arrives
• 100‐120 compressions per min• At least 2” deep (2‐2.4” with feedback device)• 30:2 ratio of compressions to ventilations
Unless there is an advanced airway…
Continuous compressions 1 breath every 6 seconds
7
Wake Forest Baptist Medical Center
The cavalry has arrived…
1. Give Oxygen
2. Attach the monitor/defibrillator
3. Identify the rhythm…
8
Wake Forest Baptist Medical Center
Wait… who are the cavalry?
Ideally you will have…• Airway
• Compressor
• Monitor/Defibrillator
• Medications
• Timer/Recorder
• Team Leader
9
4
Wake Forest Baptist Medical Center
Shockable Rhythms
10
Wake Forest Baptist Medical Center 11
SHOCK!!CPR for 2 min
IV/IO Access
Pulse/Rhythm check
SHOCK!!
CPR for 2 min
Epinephrine 1mg every 3‐5 min
Pulse/Rhythm check
SHOCK!!
CPR for 2 min
Amiodarone 300mg IVP
Pulse/Rhythm check
SHOCK!!
CPR for 2 min
Epinephrine 1mg every 3‐5 min
Pulse/Rhythm check
SHOCK!!
CPR for 2 min
Amiodarone 150 mg IVP
Pulse/Rhythm check
Wake Forest Baptist Medical Center
Non‐Shockable Rhythms
12
This isn’t TV…
5
Wake Forest Baptist Medical Center 13
CPR for 2 min
IV/IO Access
Pulse/Rhythm check
CPR for 2 min
Epinephrine 1mg every 3‐5 min
Pulse/Rhythm check
Pulse/Rhythm check
CPR for 2 min
H’s & T’s
CPR for 2 min
Epinephrine 1mg every 3‐5 min
Pulse/Rhythm check
CPR for 2 min
H’s & T’s
Wake Forest Baptist Medical Center
WHY DID THIS HAPPEN!?!
H’s T’s
Hypovolemia Tension Pneumothorax
Hypoxia Tamponade (Cardiac)
Hydrogen Ion’s (Acidosis) Toxins
Hypo‐ / Hyperkalemia Thrombosis (Pulmonary)
Hypothermia Thrombosis (Coronary)
Hypoglycemia Trauma
14
Wake Forest Baptist Medical Center
THEY HAVE A PULSE!!!
15
Place an airway if not already
done
Maintain Oxygen
Saturation & Capnography
Maintain Blood Pressure
Get an EKG
STEMI
CATH LAB!
ICU
Not a STEMI
ICU
AIRWAY
BREATHING
CIRCULATION
6
Wake Forest Baptist Medical Center
Post Cardiac Arrest Care…
The fun isn’t over yet…
Now you have to keep them alive!
16
Wake Forest Baptist Medical Center 17
http://cpr.heart.org/AHAECC/CPRAndECC/General/UCM_477263_Cardiac‐Arrest‐Statistics.jsp
Wake Forest Baptist Medical Center
Now let’s do this a bit differently…
Top 10 people you DO NOT want to be while running a code…
18
7
Wake Forest Baptist Medical Center
Mr. Freeze
ComicBook. “Arnold Schwarzenegger's Mr. Freeze Costume Almost Killed Him.” DC, ComicBook.com, 5 Sept. 2017, comicbook.com/dc/2017/06/20/arnold‐schwarzeneggers‐mr‐freeze‐costume‐almost‐killed‐him/.
19
Wake Forest Baptist Medical Center
Super Saiyan (high energy)
dbz‐dokkanbattle.wikia.com/wiki/Stunning_Metamorphosis_Super_Saiyan_3_Goku.
20
Wake Forest Baptist Medical Center
Out of control guy/girl
“Pyramids Harlem Shake ‐ Egypt ‐ .YouTube, YouTube, 22 Feb. 2013, www.youtube.com/watch?v=9DSrW_eJJy4 ”.هرم شيك
21
8
Wake Forest Baptist Medical Center
The Multi‐tasker
“The Multi‐Tasker.” Thrive With ADD, 5 Feb. 2012, thrivewithadd.com/multi_tasker_lg/.
22
Wake Forest Baptist Medical Center
The Know‐It‐All
www.faithfellowshipministries.net/new‐blog/2014/7/21/dont‐be‐a‐know‐it‐all.
23
Wake Forest Baptist Medical Center
The Houdini
www.oliverbmagic.com/2017/06/22/makes‐magic‐popular/.
24
9
Wake Forest Baptist Medical Center
The Accessorizer
i.pinimg.com/736x/bc/2d/1e/bc2d1e7b25f24521025c4f0346aaf8bb‐‐cool‐stuff‐off‐road‐jeep.jpg.
25
Wake Forest Baptist Medical Center
The Bicarb Guy
Cain depicted after killing his brother by Henri Vidal, Tuileries Garden, Paris
en.wikipedia.org/wiki/Facepalm.
26
Wake Forest Baptist Medical Center
The Mime
www.gettyimages.com/detail/photo/mime‐shrugging‐high‐res‐stock‐photography/523428206.
27
10
Wake Forest Baptist Medical Center
The Never Gonna Give You Up
28
Wake Forest Baptist Medical Center
Debriefing
“Debriefing following a simulation event is a conversational period for reflection and feedback aimed at sustaining or improving future performance.”
Palaganas, J., Fey, M., Simon, R. Structured debriefing in simulation‐based education. Advanced Critical Care. 2016;27:78–85.
29
Wake Forest Baptist Medical Center
“Deep learning can be achieved during debriefing and often depends on the facilitation skills of the debriefer…”
Palaganas, J., Fey, M., Simon, R. Structured debriefing in simulation‐based education. Advanced Critical Care. 2016;27:78–85.
30
11
Wake Forest Baptist Medical Center
“…poorly facilitated debriefings may create adverse learning, generate bad feelings, and may lead to a degradation of clinical performance, self‐reflection…”
Palaganas, J., Fey, M., Simon, R. Structured debriefing in simulation‐based education. Advanced Critical Care. 2016;27:78–85.
31
Wake Forest Baptist Medical Center
Debriefing – 3 Main Phases
• Reactions Phase
• Understanding Phase
• Summary Phase
Palaganas, J., Fey, M., Simon, R. Structured debriefing in simulation‐based education. Advanced Critical Care. 2016;27:78–85.
32
Wake Forest Baptist Medical Center
Unique Scenarios
33
1
Leading Together: Views From The American College Of Physicians
Darilyn V. Moyer, MD, FACP
EVP/CEO American College of Physicians
1
Many Thanks!
• To all on the frontlines of care who do the heavy lift of patient care
• To all members, staff and leadership at the ACP
2
Disclosures
• I am a full time staff member of the American College of Physicians
• I have no financial interests to disclose
3
2
Educational Objectives
• Review trends in healthcare financing and costs, industry consolidation, and advocacy initiatives
• Review provocative trends in the democratization of healthcare including telehealth, healthcare teams, and “the patient will see you now,” phenomena
• Review the challenges of the GME funding and physician pipeline
4
An All Too Familiar Patient…
A 40 year old patient with type 2 DM on insulin presents to the clinic (substitute ED) for the 4th
time in 3 months with a blood sugar ~400. VS are stable, PE shows no signs of dehydration, trace ketones and 4+ glucose in UA, BMP nlexcept for BS 425.
What do you think could be going on?
5
6
3
Expand access and coverageImprove public healthSupport research and scienceOppose discriminationReduce health care disparitiesSupport primary care workforce
Lower excessive Rx pricesReform and improve paymentsImprove quality measuresReform medical liability systemMake EHRs work for doctorsReduce crushing administrative burden
ACP’s “Big Tent” advocacy agenda addresses a wide range of issuesaffecting internists and their patients . . .
And whatever else pops up!
7
Some background about ACP’s perspective
• Largest medical specialty society in the world: 148,000 members
• Represents the diversity of internal medicine
– Ambulatory generalists, hospitalists, subspecialists
– Academics, practitioners, educators, researchers, administrators
– From solo practice to large groups
– Medical students, residents, fellows, practicing clinicians, retired physicians
– Domestic and international membership
• Welcomes non‐physician affiliate members
8
ACP’s focus at a glance
• The science of medicine
– Annals of Internal Medicine
• The clinical practice of medicine
– Clinical standards, guidelines
• The education and professional development of physicians
– MKSAP, meetings and courses
• The ‘quadruple aim’ of healthcare
– Better care, better health, physician professional satisfaction, lower per capita costs
• The future of medicine
– Students, residents, fellows
• Professional satisfaction
– Payment reform, practice redesign
9
4
10
11
• Two areas of greatest expenditures and mostrapid growth: imaging and tests
Tests
Imaging
12
5
13
14
15
6
16
17
18
7
19
Physician Employment Dynamics
20
21
8
The $15 Billion Dollar GME Pyramid
22
23
24
9
2016 ACP/AAIM GME Financing Positions
• Maintain societal commitment• All payer• Try to get at true costs• Selectively lift caps• Infuse transparency• Combine DME/IME• Examine potential Performance Measures• Ignite innovation• Fund ambulatory training
25
26
27
10
28
29
The Flipped Healthcare Classroom 2017…
• The Patient Will See You Now
• DPCP
• Retail Clinics
• Telehealth
• Digital Media Resources
• Home Hospital
• Patient Wearables, etc…
30
11
31
32
How Did We Get Here? The Alliance of Acronyms…
33
12
What’s Missing From The Triple Aim?
34
What is the one professional challenge that concerns you most?
Challenge Percent
Limited time with patients 14.5
Too much paperwork 11.9
Work/life balance 11.8
Loss of physician autonomy 10.7
Physician burnout 6.9
Maintenance of certification (MOC) 5.8
Malpractice threats/need to practice defensive medicine 5.6
Staying current on clinical knowledge 5.5
Electronic health records (EHRs) 4.7
Physician reimbursement and payment issues 4.1
Source: ACP 2015 Member Survey 35
At the Pediatrician’s Office: Where’s My Doctor?
• The present? The future?
© 2011 Thomas Murphy, MDSource: JAMA 2012;307:2497-8Used with permission.
36
13
http://annals.org/aim/article/2614079/putting-patients-first-reducing-administrative-tasks-health-care-position-paper
37
38
What does this practically mean for your practices?
• The number 1 thing that can be done to improve physician satisfaction with practice is to ease unnecessary regulations and tasks.
• Patients will also benefit as their physicians are able to spend more time with them with less distraction.
• Making EHRs more clinically relevant and useful requires that we examine and simplify the embedded federally‐mandated documentation requirements.
• We also need an entirely new way of looking at administrative tasks, to assess their intent, impact and possible alternatives.
39
14
40
Source: California HealthCare Foundation 41
Strategies To Reduce Burnout
• Align leadership values with clinicians’ values– Leaders model work‐home balance; value well‐being – Understand and promote work control– Alter our “culture of endurance”
• Support work‐home balance– Support needs of parent clinicians– Offer flexible/part‐time work options
• Wellness focus – reflection, exercise, share concerns with colleagues
Linzer et al. Acad Med 2009;84:1395‐1400; Saleh et al. Clin Orthop Relat Res 2009;467:558‐65; Viviers et al. Can J Ophthalmol 2008;43:535‐46; LeMaire J. BMC HSR. 2010; 10:208
42
15
Make internal medicine practice more satisfying…
• Clinical documentation
• EHRs: functionality, usefulness, clinical relevance
• Patients Before Paperwork ( Captures all of ACP’s activities to reduce administrative burdens)
• Payment reform: pay more for cognitive care, chronic care
• Quality measures: relevance, burden of reporting
43
Have Empathy and Each Day Do Something for Another
44
An All Too Familiar Patient…
A 40 year old patient with type 2 DM on insulin presents to the clinic (substitute ED) for the 4th
time in 3 months with a blood sugar ~400. VS are stable, PE shows no signs of dehydration, trace ketones and 4+ glucose in UA, BMP nlexcept for BS 425.
What do you think could be going on?
45
16
46
47
Stemming The Escalating Costs of Prescription Drugs‐ A Classic Case of
Grass Roots Advocacy• Several years ago, several members of an ACP Chapter brought this topic to their Health and Public Policy Committee
• The ACP Chapter submitted this as a resolution to the ACP Board of Governors for policy development
• The Board of Governors and Board of Regents passed the resolution
• In 2016, this became policy for the ACP
48
17
49
50
Impact of Obamacare in Four Maps, The Upshot, New York Times. October 31, 2016. http://www.nytimes.com/interactive/2016/10/31/upshot/up-uninsured-2016.html?action=click&contentCollection=upshot®ion=rank&module=package&version=highlights&contentPlacement=1&pgtype=sectionfront&smid=tw-upshotnyt&smtyp=cur
51
18
http://kff.org/health-reform/poll-finding/kaiser-health-tracking-poll-november-2016/?utm_campaign=KFF-2016-November-Tracking-Poll&utm_content=48711492&utm_medium=social&utm_source=twitter
52
53
Who loses if insurers can again waiver coverage or charge more for preexisting conditions? Your patients.
54
19
In 2002, an Institute of Medicine review concluded that lack of insurance increases mortality, but several relevant studies have appeared since that time. This article summarizes current evidence concerning the relationship of insurance and mortality. The evidence strengthens confidence in the Institute of Medicine's conclusion that health insurance saves lives: The odds of dying among the insured relative to the uninsured is 0.71 to 0.97.
Woolhandler S, Himmelstein DU. The Relationship of Health Insurance and Mortality: Is Lack of Insurance Deadly?. Ann Intern Med. [Epub ahead of print 27 June 2017] doi: 10.7326/M17-1403
55
Travel ban: health impact
56
These IM residents (ACP members) were prohibited from re‐entering the US because of the Executive Order
57
20
ACP: A Global Community
• International chapters: Bangladesh, Brazil, Caribbean, Canada (6), Central America, Chile, Colombia, India, Japan, Mexico, Saudi Arabia, Southeast Asia, and Venezuela
Over 14,000 ACP members reside outside the United States
58
Big wins for advocacy! Courts block insurer mega‐mergers
59
All in month’s work: 30 days of ACP advocacy: September 6 to October 6,
2017• Spoke out on Hate Crimes as a Public Health Issue
– September 5 statement on Charlottesville https://www.acponline.org/advocacy/acp‐advocate/issue/article/726073
• Defended “Dreamers”
– September 5 statement on President Trump’s decision to end DACA https://www.acponline.org/advocacy/acp‐advocate/issue/article/726647 , letter to Congress in support of DREAM Act https://www.acponline.org/acp_policy/letters/joint_letter_to_congressional_leaders_supporting_dreamers_2017.pdf and joint letter https://www.acponline.org/acp_policy/letters/joint_letter_to_congressional_leaders_supporting_dreamers_2017.pdf
60
21
All in month’s work: 30 days of ACP advocacy: September 6 to October 6,
2017• Advocated for Safety‐Net and Primary Care Training Programs
– September 5 Joint Letter to Congress https://www.acponline.org/acp_policy/letters/joint_letter_to_congress_supporting_extension_of_safety_net_programs_2017.pdf
– September 28 coalition letter to Congress https://www.acponline.org/acp_policy/letters/letter_to_house_and_senate_leaders_on_ex
piring_primary_care_workforce_programs_2017.pdf and ACP letter https://www.acponline.org/acp_policy/letters/letter_to_house_and_senate_leaders_on_expiring_primary_care_workforce_programs_2017.pdf
• Advocated to Reverse Cuts in Medicare payments to Clinical Labs– September 11 sign on letter to CMS,
https://www.dropbox.com/s/0hjl1bxl0um9fmy/PAMA%20POL%20Letter%20Aug%202017%20final.pdf?dl=0
61
All in month’s work: 30 days of ACP advocacy: September 6 to October 6,
2017• Advocated for Better Medicare Payments for Internists’ Services
– September 11, Comments on Medicare Physician Fee Schedule https://www.acponline.org/acp_policy/letters/comment_letter_to_cms_re_cy_2018_medicare_pfs_proposed_rule_2017.pdf
• Advocated for Better Quality Measurement– September 14 “Friends of NQF” letter urging continued mandatory funding for
NQF’s quality and measurement work https://www.acponline.org/acp_policy/letters/joint_letter_to_speaker_ryan_supporting_nqf_funding_2017.pdf
• Spoke Out Against Discrimination– Opposed President Trump’s decision to ban Transgender persons from military;
Sent two letter on September 14 letters in support of bills to overturn it https://www.acponline.org/acp_policy/letters/letter_to_senators_gillibrand_and_collins_supporting_transgender_servicemembers_amendment_2017.pdf and https://www.acponline.org/acp_policy/letters/letter_to_senators_mccain_and_reed_supporting_transgender_servicemembers_amendment_2017.pdf
62
All in month’s work: 30 days of ACP advocacy: September 6 to October 6,
2017• Supported Legislation to Lower Prescription Drug Prices
– September 19 joint letter supporting CREATES Act, “For too long, brand‐name pharmaceutical manufacturers have exploited patient safety tools in order to stifle generic competition and attendant lower prescription drug prices.”https://www.acponline.org/acp_policy/letters/joint_letter_to_senate_leadership_supporting_creates_act_2017.pdf
• Proposed policies to improve the Medicare Advantage Program
– New position paper published on October 2 with recommendations to bring introduce greater transparency and impose fewer administrative demands on clinicians in the MA program. https://www.acponline.org/acp‐newsroom/american‐college‐of‐physicians‐says‐medicare‐advantage‐should‐increase‐transparency‐align‐and‐reduce
63
22
All in month’s work: 30 days of ACP advocacy: September 6 to October 6,
2017• Advocated to protect access to health care for women including opposing
proposals to defund Planned Parenthood, eliminate coverage for contraception and other essential benefits.
– September 22 joint coalition letter to Congress https://www.acponline.org/acp_policy/letters/joint_womens_health_providers_coalition_letter_to_senate_opposing_graham_cassidy_2017.pdf
– October 6 letter opposing interim final rule to allow employers to waive contraception coverage https://www.acponline.org/acp‐newsroom/american‐college‐of‐physicians‐objects‐to‐overhaul‐of‐contraception‐mandate
• Countered the administration’s decisions to reverse commitment to mitigating health impact of climate change.
– Updated climate change action kit available at this meeting reflects latest evidence, proposes actions to counter the administration’s decision to pull out of Paris Accord and other commitments https://www.acponline.org/advocacy/advocacy‐in‐action/climate‐change‐toolkit
64
All in month’s work: 30 days of ACP advocacy: September 6 to October 6,
2017• Called for improved disaster relief response for Puerto Rico and U.S. Virgin
Islands
– September 28 letter to the President https://www.acponline.org/acp_policy/letters/letter_to_president_trump_urging_additional_hurrican
e_relief_support_for_puerto_rico_usvi_2017.pdf, continually updated resources for members https://www.acponline.org/acp‐newsroom/supporting‐hurricane‐aid‐efforts
• Advocated to Improve Medicare’s Quality Payment Program (MACRA)
– Signed onto October 2 letter organized by AMA seeking targeted legislative fixes. https://www.dropbox.com/s/hnsk73phmljlpge/MACRA_EAC%20‐%20Final%20Letter.pdf?dl=0
– Builds on ACP’s previous comments to CMS.
65
All in month’s work: 30 days of ACP advocacy: September 6 to October 6,
2017• Led the effort within American medicine, in alliance with
broader health care community, to stop efforts repeal the ACA and rollback coverage and protections for millions of patients. Sixteen letters from ACP, or ACP and our coalition members, in the last month alone!
66
23
Part of the EHR solution: simplify documentation requirements
Reworking Evaluation & Management (E/M) Documentation Guidelines:
Based on Clinical Documentation in the 21st Century the College has held numerous
meetings with the deputy administrators at CMS and other agencies within HHS
regarding reducing the administrative burden of the E/M documentation guidelines.
– On June 28, 2017 ACP attended a meeting with HHS where the College outlined a
proposal to move forward with reform of E/M documentation guidelines.
– This has led to Solicitation of Public Comment on the reform of the E/M
documentation guidelines through the 2018 Medicare Physician Fee Schedule
NPRM.
– ACP will provide detailed comments and recommendations for simplification and
alignment of E/M documentation through the rulemaking process
Link to paper: http://annals.org/aim/article/2089368/clinical‐documentation‐21st‐century‐executive‐summary‐policy‐position‐paper‐from
67
Expand access and coverageImprove public healthSupport research and scienceOppose discriminationReduce health care disparitiesSupport primary care workforce
Lower excessive Rx pricesReform and improve paymentsImprove quality measuresReform medical liability systemMake EHRs work for doctorsReduce crushing administrative burden
ACP’s “Big Tent” advocacy agenda addresses a wide range of issuesaffecting internists and their patients . . .
And whatever else pops up!
68
69
24
Resources for Educators
• Teaching Medicine SeriesTheory and Practice of Teaching Medicine, Teaching Methods, Teaching in the Hospital, Teaching in the Clinic, Teaching Clinical Reasoning, Mentoring in Academic Medicine, and Leadership in Medical Education
• Annals of Internal Medicine teaching tools • Internal Medicine In‐Service Training Examination for
residents• ACP Board Prep Curriculum for residents• High Value Care Curriculum for trainees at all levels• IM Essentials for medical students
70
Recent ACP Policy Papers
• Addressing the Increasing Burden of Health Insurance Cost Sharing (July 2016)
• Financing U.S. Graduate Medical Education: A Policy Position Paper of the Alliance for Academic Internal Medicine and the American College of Physicians (May 2016)
• Climate Change and Health: A Global Call to Action (April 2016)
• Stemming the Escalating Cost of Prescription Drugs (March 2016)
• Medicaid Expansion: Premium Assistance and Other Options (March 2016)
71
Advocates for Internal Medicine Network (AIMn)
• Grassroots advocacy network designed to help ACP members engage with federal lawmakers on policy issues important to internists
• AIMn members receive legislative updates and alerts as key policy issues unfold, including sample messages to members of Congress
• Enroll at https://cqrcengage.com/acplac/
• To learn more, contact Shuan Tomlinson:• Tel: 202‐261‐4547
• Email: [email protected]
72
25
ACP’s New Online Learning Center
• Available at ACPOnline.org/OLC• Enhanced search and browsing
functionality for ACP’s online learning• Easy access to more than 350 activities,
including:– Video‐based learning– Webinars– Interactive cases– Quizzes
The majority of activities offer both CME and MOC.
A centralized gateway for ACP’s online learning activities
ACPOnline.org/OLC
73
Resources to Help You Transform Your Practice: Prepare for New Payment
SystemACP is helping you transform your practice, choose the right path, keep up‐to‐date and meet deadlines through tools and resources: (ACPOnline.org/MACRA)• MACRA/QPP Information: Online FAQs, fact sheets, webinars
(live and recorded), articles in ACP publications • Practice Transformation: Information, resources, tools to support
practices in making strategic changes to successfully care for patients in the value‐based payment environment
• New: Quality Payment Advisor: Online tool to assist practices in determining the best path to take—MIPS or APM.
• ACP Practice Advisor: Online tool to help practices analyze and improve patient care, organization and workflow
• Physician & Practice Timeline: Online tool helps track deadlines for regulatory, payment, educational and delivery system changes and requirements. Members can sign up by texting ACPtimeline(no space) to 313131 from mobile phones
74
ACP’s Main Website for the QPP
www.acponline.org/qpp 75
26
Encouraging High Value Care
Resources to help provide the best patient care while reducing health care costs: • High Value Care Online Cases: Earn free CME credits and MOC
patient safety and medical knowledge points through web‐based cases and questions
• Curriculum For Educators, Residents and Students: Created by ACP and the Alliance for Academic Internal Medicine (AAIM), features six one‐hour interactive modules
• HVC Course For Medical Students: Students evaluate the benefits, harms and costs of tests and treatment options so they can make HVC a reality in clinical practice
76
Encouraging High Value Care (cont’d)
Resources to help physicians provide the best patient care while reducing costs to the health care system:• High Value Care Coordination (HVCC) Toolkit: Resources to
facilitate more effective and patient‐centered communication between primary care and subspecialist doctors.
• Pediatric to Adult Care Transitions Toolkit: Resources to facilitate more effective transition and transfer of young adults from pediatric to adult care.
• Collaboration with Consumer Reports: A series of new High Value Care Resources to help patients understand the importance of seeking appropriate care.
77
78
27
Support the Next Generation of IM
• Encourage a young person to understand the rewards of internal medicine as a career
• Convince a medical student to see the bright future of internal medicine
• Recommend general internal medicine to a resident
• Invite another internist to become an ACP member
• Sponsor a qualified ACP Member for Fellowship (FACP)
79
ACP . . . Get Connected
• MyACP 2.0 –a personalized web experience, making it easier for members to access and discover pertinent ACP content and resources while visiting ACPOnline.org.
• ACP Member Forums
ACP Member Forums allow ACP members to instantly participate in discussions on a range of clinical, professional, and practice‐related topics.
• Join your local IM community through ACP Chapters
– Network, gain CME, develop leadership skills
– Mentor medical students and early career physicians
• Develop skills through the ACP Engagement Program
– Volunteer to help in development of ACP products
– Judge abstracts and mentor early career physicians
• Follow on social media
ACP and Annals of Internal Medicine are using social media more than ever to communicate and share information relevant to internal medicine.
80
Internal Medicine Meeting 2018:ACP’s Annual Scientific Meeting
Internal Medicine Meeting 2018April 19‐21, 2018New Orleans
Register online at https://im2018.acponline.org/
• Over 200 educational, interactive workshops and case‐based sessions and feedback on patient management problems taught by speakers
• Networking events including Women’s Networking luncheon, African American Reception and various early career events
81
28
Thank you . . .
…for your continued support of ACP and your commitment to internal medicine.
82
1
Representative Gregory F. Murphy, MD, FACSNC House of Representatives
1
NC Legislative Medical Issue Update 2018
2
Brief Overview of Politics
Versus
Legislative Branch Executive Branch
US
State
3
2
Judicial BranchSupreme Court
Essentially the ultimate decision makers
4
How are laws made?
• Issue brought up by constituent, business group, society (NCMS), environmental group, state gov agency, anyone
• Bill drafted with assistance of Staff Attorneys and then submitted to the Speaker of the House
• Assignment of Bills…Very Important…• If viewed favorably by leadership, good assigment• If not viewed favorably, often sent to the Rules Committee where bills
usually die
5
6
3
Committee Meetings
7
Floor DebateFloor Debate
Each Bill has to be voted on THREE times on three separate days (rare circumstances…HB2)
Sometimes debate quick and noncontroversial, others debate well into the night…
Majority Party usually gets its way if issue controversial
Once a Bill passed in the House it is sent over to the Senate for the WHOLE process to start over (Committee Assignment, etc)
Bill can die there, be changed mildly or substantially
8
Final Stages of a Bill
Governor signs into Law
Governor Vetoes
Unfortunately still can be very partisan
9
4
10
Historical Political Involvement by Physicians
*In 1776, 11 percent of signers of the Declaration of Independence were physicians.
*In 1787 5 percent of the individuals crafting the US Constitution were physicians.
113th Congress (2013 – 2015)From 2013‐2015 there were 21 physicians in U.S.Congress, 20 of whom were male and 17 were members of the Republican party.114th Congress (2015 – 2017)From 2015‐2017, there were 18 physicians in U.S. Congress. All were male and 15 were members of the Republican party. (38% Lawyers)115th Congress (2017 – 2019)From 2017‐2019 there were 15 physicians in U.S. Congress, all were male and 13 were members of the Republican party. (3% Physicians)
Neal Dunn, MD (R), 2017‐2018 US Congress2nd District Florida
11
12
5
13
14
15
6
Legislative Successes
16
Senate Bill 33 2011Malpractice Reform
17
North Carolina Senate Bill 332011
Caps on noneconomic damageSB 33 caps compensation for noneconomic damages at $500,000. “Noneconomic damages” refers to compensation for pain, suffering, personal loss, professional loss or anything else that cannot be defined monetarily.
Immunity for emergency personnelIn addition to the cap, SB 33 gave extra protection to emergency personnel by putting tougher standards to prove medical malpractice in an emergency situation. Plaintiffs must prove “gross negligence” when pursuing a malpractice case classified as an emergency.
18
7
North Carolina Senate Bill 332011
Almost didn’t happen:Although passed in Senate and then in House BUT—Vetoed by Governor Bev Perdue
NCMS and other Stakeholders went into actionurging physicians to visit their legislators and made their voices heard one on one
Veto Overridden!!! 74‐42
Physician Advocacy Works!!!!!
19
North Carolina Senate Bill 332011
Results:
55‐65% decrease in malpractice cases since 2011
Stabilization of Malpractice RatesMedical Mutual Investment Program
2014 marked the second consecutive year that malpractice payout amounts in the U.S. rose, according to Diederich Healthcare. However, North Carolina was one of four states in which payouts fell.
IN NC a total of $44,009,050 was paid in med mal claims in North Carolina in 2014 –28.67 percent less than in 2013.
20
21
8
NC House Bill 243“STOP ACT”
Opioid Epidemic in NC*4 die from Opioid Overdose each day in NC*1:100 babies born addicted to Opioids*Wilmington, NC #1 worst city in US (NC w 4 out of top 15)
SOMETHING had to be done*State Attorney General, other non‐
medical Legislators draftedup initial Legislation
*First Draft VERY burdensome to physicians
*Made sure a physician at the table to direct the
Legislation22
Physician Leadership in LegislationHouse Bill 243
23
NC House Bill 243
Initial restriction of 3 day script for Opioids*Would have been exceedingly bothersome for MD’s*Subsequently changed to 5 day restriction for Acute Pain*Post Op pain to 7 days
Required Queries of Controlled Substance Reporting System (CSRS) with each Narcotic prescription to check patients history
*Must document in EHR*Had to explain what limitations EHR’s have*Allow paper script to be used at times
Attorney General wanted to fine MD’s $250 for each instance *CSRS not queried
*Changed language to reporting to NCMB—no fine
Initially a yearly fee of $50 per doc to keep CSRS going*Negotiated that down to $20 24
9
Initial prescription limits for ACUTE PAINCSRS Queries with each prescriptionEscribing of OpioidsWork RequirementCloser consultation with NP’s/PA’s/MD’s at Pain ClinicsBetter defined disposal of Prescribed Opioids (Hospice)Standing Order for NaloxonePharmacy Reporting with CSRS and regulationsMandatory yearly review of CSRSOver $30 Million dollars secured for Community
Substance Abuse treatment.
STOP ACT SUMMARY
25
Playing Defense
26
Playing Defense….House Bill 36
Bill to allow Optometrists to perform Laser Surgery in their Offices
Optometrists hired $750K worth of Lobbyists
Would have had profound implications if passed
As a Chair able to get it blocked completely and turned into a ‘study bill’, then died in Senate….(for now anyway)
27
10
Scope of Practice IssuesHB 88
HB 88 seeks to allow NP’s, CRNA’s and Midwives to practice without supervision.
Would fundamentally change the way Health Care is delivered in NC
28
Defense: Motor Cycle Helmet Law
Would have allowed persons 21 years and older to no longer be required to wear helmets
29
30
11
31
Other insanities….
Require out of network payments to be equal to Medicare only
“Assignment of Benefits” issue…
Allow Chiropractors to do Sports Physicals…
HB 36 and HB 88 not dead….
32
33
12
34
35
Carolina Cares HB 662
36
13
Carolina Cares HB 662
Key ComponentsAlternative to Medicaid Expansion
Health Insurance for the State’s Working Poor
Participant’s required to do health maintenance activities
Paid for by Fed return of monies to state and tax on Hospitals (2:1 return)
Participant Contributions2% of household’s income
Required
Future Unclear…..
37
So again…why did I agree to do this?....
The only physician in our entire General Assembly….
Health Care Crisis the #1 domestic issue facing our state and our nation
38
The Bottom Line…..
#1 Comment when Controversial Medical issue comes up
“I never hear from doctors unless they want something”
You have to get to know your Legislator and you MUST Contribute to their campaigns.
39
1
Treatment of Opiate Addiction: What Do We Do Now?
Michael Lang MD
Clinical Associate Professor
Internal Medicine and Psychiatry
1
Objectives
• Explore the extent of substance abuse disorders in the prescription drug population
• Identify problematic behaviors indicating substance abuse, drug seeking in the clinical setting
• Explain the diagnostic criteria for opiate abuse/dependence diagnosis
• Compare/contrast treatment measures for opiate dependence
2
What is the Risk of Addiction?
From a systematic review from 38 studies – rates of misuse, abuse, and addiction in chronic pain
Misuse rates: 21‐29%
• Opioid use contrary to the directed or prescribed pattern of use, regardless of the presence or absence of harm or adverse effects.
Addiction rates: 8‐12% • Pattern of continued use with experience of, or demonstrated potential for,
harm (ex: “compulsive use; continued use despite harm, and craving”).
Source: Vowles KE, et al, Pain 20153
2
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
Deaths per 100,000
population
Year
Motor Vehicle Traffic (Unintentional)
Drug Poisoning (All Intents)
α β
Death Rates* for Two Selected Causes of Injury, North Carolina, 1968‐2015
*Per 100,00, age‐adjusted to the 2000 U.S. Standard Populationα ‐ Transition from ICD‐8 to ICD‐9β – Transition from ICD‐9 to ICD‐10 National Vital Statistics System, http://wonder.cdc.gov, multiple cause dataset
Source: Death files, 1968‐2015, CDC WONDERAnalysis by Injury Epidemiology and Surveillance Unit
1989 – Pain added as 5th Vital Sign
Drug Overdose Deaths on the Rise
The extent of the addiction
Cicero, et al, 2014 Muhuri, et al, 2013
5
One‐and 3‐year probabilities of opioid use by duration of first episode in days
Acute Pain Treatment Leading to Long Term Use4
CDC Weekly March 17, 2017 / 66(10); 265‐269 “Characteristics of Initial Prescription Episodes and Likelihood of Long‐Term Opioid Use — United States, 2006–2015”
6
3
Risk Stratification Prior to Prescribing
7
Lower Risk Medium Risk Higher Risk
Etiology of Pain
Clear/Identified Vague/Non‐specific
Substance Abuse
Negative history Past history but
stable recovery
Active abuse or
addiction
Psychiatric Conditions None Few / Stable Multiple / Unstable
Environment Stable/Supportive/
Resources
Unstable/Few supports/
Few resources
Activity
Engagement
Employed/Active
Active self‐mgmt/
Uses non‐med modalities
Unemployed/Inactive
Poor self mgmt/
Emphasis on med only
CSRS
Initial Drug Screen
One prescriber/Low dose/No benzo.
C/W prescription history/No illicit drugs
One prescriber/Moderate dose/Benzos
>1 prescriber/High dose/Benzos/Irregularities
Not c/w prescription history/Illicit drugs
Signs of Opioid Intoxication
Physical
Pupillary Constriction
Slurred Speech
Drowsiness
Impaired Attention
Respiratory slowing
Bradycardia
Pulmonary Edema
Coma
Psychiatric
Euphoria (esp at onset)
Apathy
Dysphoria
Psychomotor agitation (onset)
Psychomotor retardation (later)
Impaired judgement
8
Risk Assessment Tools
9
4
Quantifying Function & Risk
• Pain scales• BPI, McGill Pain Questionnaire, PEG• Back Pain Functional Scale (BPFS)
• Psychiatric scales• PHQ‐9, PHQ‐4, GAD‐7
• Substance use evaluation• ORT or other scales• ETOH use• Smoking
• Aggregate data represented as single number
• Consider developing predetermined treatment actions for particular scores
Passik, Weinreb. 199810
Merrill and Duncan 2014 11
Dependence vs. Addiction
• Physical dependence is characterized by tolerance and withdrawal
• A patient can be dependent on a drug without being addicted
• Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial and environmental influences
• Aberrant behaviors: Loss of control, compulsive use, continued use despite harm, craving
12
5
Opioid Use Disorder (DSM‐V)• Taken in larger amounts or for longer periods
• Persistent desire/unsuccessful efforts to reduce usage
• Great deal of time spent obtaining/using opioids
• Craving, or strong desire to use opioids
• Failure to fulfill work/home obligations due to opioid use
• Lack of concern for problems due to recurrent opioid use
• Lack of interest in activities that used to be important
• Recurrent use of opioids despite hazards
• Continued use despite known problems due to opioid use
APA DSM 5 workgroup 201313
Opioid Use Disorder (DSM‐V)• Tolerance (except for those under medical supervision)
• Markedly increased amounts to achieve desired effect
• Markedly diminished effect with continued use at same amount
• Withdrawal (except for those under medical supervision)• Characteristic opioid withdrawal syndrome
• Opioids are taken to relieve or avoid withdrawal syndrome
Mild OUD: 2‐3 CriteriaModerate OUD: 4‐5 CriteriaSevere OUD: >6 Criteria
APA DSM 5 workgroup 2013
14
Communication About Addiction
• Focus on “benefits/risk” mindset
• Address patient behaviors which raise concerns about abuse (running out, “lost” scripts, etc.)
• Remember that patients may suffer from both chronic pain and addiction
• Intervention based on level of risk and concern for safety: “I cannot responsibly continue prescribing opioids because I feel it would cause more harm than good”
• Always offer referral to treatment
• May need to abandon risky treatment, but not patient.• Maximize non‐opioid treatment options
Merrill, Duncan 2014
15
6
Does My Patient Need to Stop?
Criteria to consider discontinuing long‐term opioid therapy: Inability to achieve or maintain expected pain relief or functional improvement despite dose escalation• Intolerable adverse effects at the minimum dose that produces effective
analgesia• Persistent non‐adherence with patient treatment agreement• Deterioration in physical, emotional or social functioning attributed to
opioid therapy• Resolution or healing of the painful condition
Berna, et al. 201516
Does My Patient Need to Taper?
• Use shared decision making as much as possible in planned taper; set expectations
• Individualize tapering plans based on patient goals, concerns, and length of time on opioid therapy
• Speed of taper depends on level of concern vs. apparent risk of harm (consider detox trt at this point)
• Build up alternative pain treatment modalities
• Consider treatment for substance use disorder if present
• Communicate clearly with patient and document plan
Berna, et al. 201517
Opioid Overdose Reversal: Naloxone HCL
• Mu‐opioid receptor antagonist
• Can’t get ‘high’ from it (no potential for abuse)
• Quick acting, acts in 3‐5 minutes
• Delivered via injection 0.4 mg (IM, SC, IV) or nasal 2/4 mg
• NC: no prescription required under standing order
• www.naloxonesaves.org
18
7
ASAM Guideline
• Developed to guide management for opiate overdose and treatment of opiate use disorders
• Diagnostic recommendations (Part 1)• History and assessment of behavior• DSM 5 criteria• Quantify using a validated scale
• Objective Opioid Withdrawal Scale (OOWS)• Clinical Opioid Withdrawal Scale (COWS)
• Urine drug screens• Type of screen, cost are considerations
Kampman, Jarvis 2015 19
ASAM Guideline
• Comprehensive assessment (part 1)
• Full medical history & exam• Focus on Hepatitis, HIV, TB, acute trauma, pregnancy
• Identify co‐morbid psychiatric disease
• Full substance use history• Concurrent use etoh, sedatives, hypnotics, anxiolytics
• Tobacco use
• Identify facilitators and barriers to treatment
Kampman, Jarvis 201520
Social/Environmental Factors
• Barriers• Government regulations
• Insurance costs
• Lack of Pharmaceutical industry interest
• Provider education/experience
• Treatment philosophy
• Logistical issues
• Lack of patients awareness
Oliva, Gordon 2011
21
8
Part 2: Select the Appropriate Level of Care
Kampman, Jarvis 2015 22
Part 3: Manage Opiate Withdrawal
Koston, George. 2002 Kampman, Jarvis 2015 23
Opiate Detoxification
• Four commonly used strategies• Methadone substitution
• Clonidine
• Clonidine/Naltrexone combination
• Buprenorphine
• Little risk of adverse medical consequences
• Goals• Stabilization
• Preparation for long term treatment
Kampman, Jarvis 201524
9
Opiate Detoxification
Methadone Substitution
• Long duration action• Smoother transition
• Start at 20‐40mg/day• Lethal in non addicts
• Adjust dose over next few days based on symptoms
• Adjust 10‐15% per week
• Advised only for use in highly addictive items
• Heroin, Demerol
Clonidine• Alpha receptor agonist
• 0.1‐0.3 q6‐8 hrs
• Serves to reduce sympathetic output• Fast heart rate, BP• N/V/D/belly cramps• Sweats, chills
• Most common side effects• Sedation low BP
• For less addictive items• Codeine, Oxycodone
Fishbain et al 2011 Kampman, Jarvis 2015 25
Opiate Detoxification
Clonidine/Naltrexone
• Combo addresses shortcomings of clonidine
• Shortens time to detox• Often 2‐3 days
• First 8 hours can be risky• Naltrexone can cause massive w/d and lower BP
• May need meds for cramps• Alternative to Methadone
Buprenorphine
• Partial mu agonist• Previously only by injection
• Suboxone is outpatient mainstay
• Very Safe• Ceiling effect
• Blocks cravings • Blocks rewards• Some potential for abuse
Fishbain et al 2011 Kampman, Jarvis 201526
Opiate Treatment After Detox
• Coping strategies for stress are critical to long term abstinence
• Many of same drugs used for detox are adjusted for abstinence• Methadone maintenance
• Suboxone clinics
• All MAT options must be accompanied by case‐appropriate psychosocial interventions to achieve best outcome
Kampman, Jarvis 2015
27
10
Can Psychosocial Intervention Truly Benefit?
• Kentucky Medicaid Wellcare Initiative
• 1300 members identified as high risk• Connected to 1 pharmacy, 1 provider, 1 care manager
• Care manager set up required engagement in community services• Counseling, social services, exercise
• Results• 50% reduction opiate prescribing
• 35% drop in cyclobenzaprine prescribing
• 30% drop in benzodiazepine prescribing
Walker 201728
The Therapy Component
• Group & Individual Therapy• Critical for relapse prevention
• Address psychological, social factors
• No one approach is best for all patients
• In general group > individual
• Group allows for peer support, guidance
• Individual best for focus on co‐morbid dx
• Most evidence based interventions
• Cognitive behavioral therapy
• Motivational interviewing
• Contingency management
• Harm reduction
• 12 step facilitation/12‐step programs
• Relapse prevention
Dutra et al 2008Merrill, Duncan 2014
29
Detox to Maintenance: Buprenophine
30
11
Methadone Maintenance• 40 years of clinical data
• Still significant stigma
• Separated from other med settings
• Duration 24‐36hrs• Given dose to prevent w/d
• Urine screens frequently
• Daily dosing
• Target dose 60‐120mg
• Visit frequency on continuum
• Given in licensed facility only!
Merrill, Duncan 2014Fullerton, Kim, Thomas 201431
Naltrexone
• Originally designed for opiate addiction
• Also blocks reward of alcohol effect on enkephalins
• Can see effect within 7‐10 days
• 60% response rate
• Serious side effects rare• Liver injury
• Best choice‐motivated pt, short hx of abuse
• Extended release injection if adherence is a concern
DeWitt, et al 2005. Kampman, Jarvis 201532
The Multimodal Team
33
12
Substance Abuse & Psychiatric Co‐Morbidity
34
Kessler, 2000
Psychiatric Co‐morbidity of SA
• Most prevalent psychiatric disorders in US:• Substance use disorders
• Mood disorders
• Anxiety disorders
• These tend to merge with time
• Any & all require attention & possible treatment
Anxiety Mood
SUD
Co‐Morbidity: The Chicken or The Egg?
• Given a substance dependent patient• Comorbidity is the norm• Although not absolute
• Faced with a chronic substance abuser endorsing psychiatric symptoms• Did drug induce the problem?• Did problem predate the drugs?
• Self medicating
• First verify safety• Substance treatment facility vs. behavioral health unit
• Monitor carefully for drug‐drug interactions
• Consider ACT teams for these patients
Kampman, Jarvis 201536
13
Substance Abuse & Chronic Pain• Can be very difficult to tease out• Standard is to treat objectively‐ verify diagnosis
• Exam findings• Labs, X‐Rays
• Take substance abuse history into account• NSAIDs, acetaminophen if feasible• Ideally stop buprenorphine and use high potency opiate
• If needed realize dosing will need to be higher given tolerance
• If active opiate use disorder & not in treatment‐methadone, buprenorphine
• Allowable with close scrutiny‐especially if outpatient setting
• Pain contracts• Frequent re‐evaluation and treatment
Kampman, Jarvis 2015 37
Special Population: Pregnancy
• Medical evaluation (status of pregnancy) and psychosocial assessment 1st
• GYN involved early• HIV, Hepatitis, other STDs
• Position on reporting substance use in pregnancy• Given pregnancy proceed to maintenance rather than withdrawal management
• Methadone preferred• Buprenorphine second line• Avoid naloxone unless in setting of OD
• Have a low threshold for hospitalization especially in 3rd trimester
38
Special Population: Adolescents
• Psychosocial treatments are mandatory and vital• Should be instituted first and maintained• Often teens are seen in more specialized facilities with multimodal services
• The full spectrum of pharmacotherapy options should be considered
• Methadone and buprenorphine included
• A special focus of health maintenance should be STD risk reduction
Kampman, Jarvis, 201539
14
Special Population: Criminal Justice System
• MAT has been shown to be effective in correctional setting
• Just as in other setting psychosocial treatment should work as adjunct to MAT
• No one medication option is show as superior or safer
• MAT should be maintained especially once paroled• Should be started minimum 30 days prior to release
• Structured follow‐up must be in place
Kampman, Jarvis 2015
40
New Horizons‐ Separating Analgesia from Addiction
NKTR‐181
• Phase 3 trials currently for mod‐severe chronic pain
• Low permeability/slow entry across BBB
• Reduced effect on dopamine release
• 42 recreational drug users• 3 doses of NKTR vs. Oxycodone 40mg
• Drug liking score sig lower for all but 400mg dose
CR845
• Selectively activates K‐opioid receptor (KOR)• No activity at mu receptor• Can’t cross BBB
• Given IV for lap hysterectomies and bunionectomies
• 4 way x‐over design for 44 recreational drug users• Placebo, 5mcg/kg CR8, 15mch/kb CR8, 0.5mg/kg
Pentazocine• Drug liking scores sig best for Pentazocine, placebo and
CR8 essentially equal
Bender, July 2017 41
New Horizons‐ NSS‐2 Bridge Neurostimulator
• FDA approved November 2017• 73 patients 5 treatment centers• Withdrawal scale scores dropped 63% after 20 min of use compared to sham
• 88% pts successfully moved to MAT• Based on concept of auricular acupuncture
• Intended for short term use only• Battery dies after 120 hours• 2nd Rx for those transitioning off methadone
• No significant adverse effects for duration of therapy
Zagorski 201842
15
Clinicians should consider offering naloxone to which of the following patient groups?
• History of opioid overdose
• History of substance use disorder
• Higher opioid dosages (≥50 MME/day)
• Any dose of an opioid + benzodiazepine
• All of the above
Coffin P, et al 2016
43
Chronic pain patients with current opioid addiction can get the best benefit from which of the following interventions?
• Detoxification from opioids followed by opioid analgesic therapy
• Buprenorphine treatment along with behavioral interventions
• Methadone taper followed by naltrexone
• Benzodiazepine and SSRI combination
Kampman, Jarvis 2015
44
A Few Final Points
• Opioid use disorder is a chronic, potentially fatal, but treatable condition associated with a significant genetic predisposition that is on the rise.
• Keep diagnostic criteria in mind and engage patients early
• MAT with buprenorphine, methadone or naltrexone reduces mortality and improves health & social outcomes
• Federal and state regulations draw sharp distinction between use of opioids to treat pain vs. opioid use disorder.
• DEA‐registered MD, PA, NP may access free training to qualify for DATA 2000 waiver to prescribe buprenorphine for opioid use disorder.
45
16
Thank You For Your Attention
Questions or Comments
46
• Chang, H.‐Y., Daubresse, M., Kruszewski, S. P., & Alexander, G. C. (2014). Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. The American Journal of Emergency Medicine, 32(5), 421–431. https://doi.org/10.1016/j.ajem.2014.01.015; Daubresse, M., Chang, H., Yu, Y., Viswanathan, S., Shah, N. D., Stafford, R. S., … Alexander, G. C. (2013). Ambulatory Diagnosis and Treatment of Nonmalignant. Medical Care, 51(10), 870–878.
• Teater D. Evidence for the Efficacy of Pain Medications. Itasca, Illinois; 2014. http://media.wix.com/ugd/cb52b5_8a3726bdfc2c47fa9da81547e622cb45.pdf;
• Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev. 2011;9(9):CD008659. doi:10.1002/14651858.CD008659.pub2.
• Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long‐Term Opioid Use — United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66(10):265‐269.
• Passik & Weinreb, Four A’s of Pain, 1998
• Vowles KE et al Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis Pain. 2015. https://www.ncbi.nlm.nih.gov/pubmed/25785523
• Tapering Long‐term Opioid Therapy in Chronic Noncancer Pain, Berna C, et al. Mayo Clin Proc. 2015. http://www.mayoclinicproceedings.org/article/S0025‐6196(15)00303‐1/pdf
References
47
References• Zagorski, Nick. FDA Clears Way for Stimulation Device to Treat Opioid Withdrawal Symptoms. Psychiatric News. Vol 53, Num 1. January 5, 2018. p 20.
• Bender, Kenneth. Opioid Research Seeks to Separate Analgesia from Addiction. Neurology & Psychiatry. Vol 7, issue 4. July, 2017. p 25‐26.
• Kampman, K. Jarvis, M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addiction Med. Vol 9, Num 5. Sept/Oct 2015 p358‐367.
• Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821‐826
• ‐Muhuri PK, Gfroerer JC, Davies MC; Substance Abuse and Mental Health Services Administration. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical‐pain‐reliever‐use‐2013.pdf. Published August 2013. Accessed October 8, 2015.
• Merrill, Joseph. Duncan, Mark. Addiction Disorders. Med Clin N Am. 98 (2014) 1097‐1122.
• Berna C, et al. Mayo Clin Proc. 2015• Coffin, P. et al. Non randomized Intervention Study of naloxone Coprescription for Primary Care Patients Receving Long Term Opioid Therapy for Pain. Annals of Internal Medicine. Vol 165. No 4. August 2016. p245‐252
48
17
References
• Oliva, E. Gordon, A. Barriers to use of Pharmacotherapy for Addiction Disorders and How to Overcome Them. Current Psychiatry. July, 2011. 13:374‐381.
• DeWitt, P. et al. CNS Drugs. 2005. 19:517‐537
• Costen, T. George, T. The Neurobiology of Opiate Dependence: Implications for Treatment. Sci Pract Perspect. July, 2002. 1(1): 13‐20.
• Fishbain, D. Rossamoff, H. Cutler, R. Rossamoff, R. Opiate Detoxification Protocols: A Clinical Manual. Annals of Clinical Psychiatry. Vol 5. 1993. Issue 1. Published online Dec 2011.
• Fullerton, CA. Kim, M. Thomas, CP. Et al. Medication‐assisted treatment with Methadone: assessing the evidence. Psychiatric Services. 2014;65(2): 146‐57.
• Kessler, R. Psychiatric Epidemiology: selected recent advances and future directions. Bulletin of the WHO. 2000. 78(4). 464‐474.
• Walker, Tracey. Program Drops Opioid Dispensing 50%. Managed Healthcare Executive. December, 2017. P37
49
1
Non‐Insulin Therapy for Type 2 Diabetes
Basem Mishriky
Clinical Assistant Professor
East Carolina University
Greenville, NC
Disclosure
• No conflict of interest
• Residency: Internal Medicine at East Carolina University
• Fellowship: Diabetes fellowship at East Carolina University
Objectives
• Discuss the rationale of non‐insulin therapy
• Review and compare two common diabetes guidelines
• Explore the different approaches for common clinical scenarios
• Review when and how to initiate newer classes
2
Insulin Resistance
• Insulin resistance in muscle and liver associated with relative β‐cell failure(collectively called “Triumvirate”) represent the core pathophysiologic defects in type 2 diabetes [1].
• The United Kingdom Prospective Diabetes Study (UKPDS 33) [2] concluded that intensive blood‐glucose control by either sulfonylurea or insulin substantially decreased the risk of microvascular complications but not macro‐vascular disease in patients with type 2 diabetes.
That is why this lecture is important!!
[1] Diabetes 2009; 58: 773. [2] Lancet 1998; 352: 837.
American Diabetes Association Dia Care 2017;40:S64-S74
©2017 by American Diabetes Association
ADA Guideline 2017
American Diabetes Association Dia Care 2018;41:S73-S85
©2018 by American Diabetes Association
ADA Guideline 2018
3
Endocrine Practice 2018; 24: 91
Case 1
• A 45‐year‐old Male with no significant past medical history who is presenting to clinic today for an annual physical exam.
• Physical exam shows acanthosis nigricans and multiple skin tags.
• Hemoglobin A1c is 8.5% (repeat is 8.4%).
• Patient is not on any medication for his diabetes.
What is the most appropriate next step in management?
ADA guideline AACE/ACE guideline
Management of newly‐diagnosed type 2 diabetes
Hemoglobin A1c is less than 9%
One agent
Preferably Metformin
American Diabetes Association Dia Care 2018;41:S73-S85
Hemoglobin A1c is more than or equal 7.5%
Two agents
Metformin AND preferably GLP‐1 RA
Endocrine Practice 2018; 24: 91
4
Case 2
• A 45‐year‐old Female who has a history of recently diagnosed type 2 diabetes who is presenting to clinic for follow up.
• Hemoglobin A1c is 8.0% (3‐months ago was 8.5%).
• Patient is on maximally tolerated dose of metformin extended release.
What is the most appropriate next step in management?
ADA guideline AACE/ACE guideline
Add‐on therapy to metformin
Diabetes is uncontrolled
On maximally tolerated metformin
Does the patient have ASCVD?
No Add an agent from the six preferred groups
American Diabetes Association Dia Care 2018;41:S73-S85
Diabetes is uncontrolled
On maximally tolerated metformin
Add an agent as suggested by the hierarchy order
Preferably add GLP‐1 RA then SGLT‐2i
Endocrine Practice 2018; 24: 91
Case 3
• A 46‐year‐old Female with history of type 2 diabetes, coronary artery disease, hypertension, dyslipidemia, and obesity.
• Her hemoglobin A1c 3 months ago was 7.5% but today is 7.8%.
• Patient is on maximally tolerated dose of metformin.
Is this patient different from the previous case?
What is the most appropriate next step in management?
5
ADA guideline AACE/ACE guideline
Add‐on therapy to metformin
Diabetes is uncontrolled
On maximally tolerated metformin
Does the patient have ASCVD?
Yes Consider adding an agent with proven cardiovascular benefit
American Diabetes Association Dia Care 2018;41:S73-S85
Diabetes is uncontrolled
On maximally tolerated metformin
Add an agent as suggested by the hierarchy order
Preferably add GLP‐1 RA or SGLT‐2i
Endocrine Practice 2018; 24: 91
Cardiovascular safety studies for GLP‐1 RATrial (# of participants)
Groups (median fu)
Characteristics MACE outcome CV mortality All‐cause mortality hHF Occurrence of MI or stroke
LEADER(9340)[1]
Liraglutidevs placebo(3.8 years)
High risk for cardiovascular disease (81.3% had CV disease)
Lira: 608/4668 (13%)Plac: 694/4672 (14.9%)HR 0.87 (0.78 – 0.97)
Lira: 219 (4.7%)Plac: 278 (6%)HR 0.78 (0.66 – 0.93)
Lira: 381 (8.2%)Plac: 477 (9.6%)HR 0.85 (0.74‐0.97)
Lira: 218 (4.7%)Plac: 248 (5.3%)HR 0.87 (0.73‐1.05)
No differences were not significant
SUSTAIN‐6(3297)[2]
Semaglutidevs placebo(2.1 years)
High risk for cardiovascular disease (83% had CV disease)
Sema: 108/1648 (6.6%)Plac: 146/1649 (8.9%)HR 0.74 (0.58 – 0.95)
Sema: 44 (2.7%)Plac: 46 (2.8%)HR 0.98 (0.65 – 1.48)
Sema: 62 (3.8%)Plac: 60 (3.6)HR 1.05 (0.74‐1.5)
Sema: 59 (3.6)Placebo: 54 (3.3)HR 1.11 (0.77‐1.61)
Significantlylower incidence for non‐fatal stroke
EXSCEL(14,752)[3]
Exenatidevs placebo(3.2 years)
With or without cardiovasculardisease (73.1% had CV disease)
Exen: 839/7356 (11.4%)Plac: 905/7396 (12.2%)HR 0.91 (0.83 – 1.00)
Exen: 340 (4.6%)Plac: 383 (5.2%)HR 0.88 (0.76 – 1.02)
Exen: 507 (6.9%)Plac: 584 (7.9%)HR 0.86 (0.77‐0.97)
Exen: 219 (3.0%)Plac: 231 (3.1%)HR 0.94 (0.78‐1.13)
No differences were not significant
ELIXA(6068)[4]
Lixisenatidevs placebo(25 months)
Had acute coronary event within 180 days before screening
Lixi: 406/3034 (13.4%)Plac: 399/3034 (13.2%)HR 1.02 (0.89 – 1.17)
Lixi: 156 (5.1%)Plac: 158 (5.2%)HR 0.98 (0.78 – 1.22)
Lixi: 211 (7.0%)Plac: 223 (7.4%)HR 0.94 (0.78‐1.13)
Lixi: 122 (4.0%)Plac: 127 (4.2%)HR 0.96 (0.75‐1.23)
No differences were not significant
[1] NEJM 2016; 375: 311. [2] NEJM 2016; 375: 1834. [3] NEJM 2017; 377: 1228. [4] NEJM 2015; 373: 2247.
Cardiovascular safety studies for SGLT‐2i and TZDTrial (# of participants)
Groups(average fu)
Characteristic MACE Outcome CV mortality All‐cause mortality hHF Occurrence of MI or stroke
EMPAREG (7020)[1]
Empagliflozinvs placebo(3.1 years)
Established CV (99%) disease
Empa: 490/4687 (10.5%)Plac: 282/2333 (12.1%)HR 0.86 (0.74‐0.99)
Empa: 172 (3.7%)Plac: 137 (5.9%)HR 0.62 (0.49 – 0.77)
Empa: 269 (5.7%)Plac: 194 (8.3%)HR 0.68 (0.57‐0.82)
Empa: 126 (2.7%)Plac: 95 (4.1%)HR 0.65 (0.5‐0.85)
No significant differencebetween groups
CANVASCANVAS‐R(10,142)[2]
Canagliflozinvs placebo(188.2 weeks)
High CV risk (65% had CV disease)
HR 0.86 (0.75 – 0.97) HR 0.87 (0.72 – 1.06) HR 0.87 (0.74‐1.01) HR 0.67 (0.52‐0.87)
No significant differencebetween groups
PROactive(5238)[3, 4]
Pioglitazone vs placebo(34.5 months)
Extensive macro‐vasculardisease
Pio: 257/2605 (9.9%)Plac: 313/2633 (11.9%)HR 0.82 (0.70‐0.97)
Pio: 127 (4.9%)Plac: 136 (5.2%)HR 0.94 (0.74‐1.20)
Pio: 177 (6.8%)Plac: 186 (7.1%)HR 0.96 (0.78‐1.18)
Pio: 149 (6%)Plac: 108 (4%)p=0.007
Pio reduced the risk of recurrent stroke [5] and recurrent MI [6].
[1] NEJM 2015; 373: 2117. [2] NEJM 2017; 377: 644. [3] Lancet 2005; 366: 1279. [4] Am Heart J 2008; 155: 712. [5] Stroke 2007; 38: 865. [6] J Am CollCardiol 2007; 49: 1772.
6
Bonus question
Intensification of diabetes medications was investigated in a retrospective analysis published in 2011 involving 12,566 patients with type 2 diabetes who were uncontrolled on metformin monotherapy.
According to this article, how long did it take to intensify treatment in uncontrolled patients?
• 3‐6 months
• 9‐12 months
• 14 months
• 16 months
[1] Diabetes Obes Metab 2011; 13: 765.
When and how to initiate Metformin
Initiation of metformin [1]:
• Start metformin 500 mg once or twice daily with meals for 1 week
• After a week, if no GI side effects, increase metformin to 1000 mg twice daily
• If GI side effects appear as doses advanced, decrease to previous lower dose.
• My way One pill of the metformin 500 mg XR once weekly to a maximum dose of 1000 mg twice daily or to a maximally tolerated dose without GI side effects
[1] Diabetes Care 2009; 32: 193
When and how to initiate GLP‐1 RA
[1] Diabetes Care 2018; 41 (suppl 1): S73. [2] Endocrine Practice 2018; 24: 91
GLP‐1 RA
Reasons to consider this group
• Reduction of hemoglobin A1c (high potency)• No hypoglycemia (except if added to SU/insulin)• Weight loss• Cardiovascular benefit (particularly with Liraglutide and Semaglutide)• Some are once weekly (Dulaglutide, Exenatide ER, and Semaglutide)
Drug‐specific and patient factors to consider
• GI side effects (Nausea, vomiting, and diarrhea)• ? Pancreatitis• Avoid in patients with personal or family history of medullary thyroid carcinoma or multiple neoplasia syndrome type 2 (MEN 2)• Injectable and expensive
Compounds • Liraglutide: Start 0.6 mg once daily for 1 week increase to 1.2 mg daily• If remains uncontrolled, may increase to 1.8 mg once daily.• No renal or hepatic dose adjustment. There is limited data in renal patients.
• Semaglutide: Start 0.25 mg once weekly for 4 weeks to be increased to 0.5 mg once weekly.• If remains uncontrolled, may increase to 1 mg once weekly.
• Exenatide extended release: 2 mg once weekly• CrCl <30 mL/min or ESRD: Not recommended
• Dulaglutide: Start 0.75 mg once weekly. • If remains uncontrolled, may increase to 1.5 mg once weekly.• No renal adjustment
• Exenatide twice daily: Start 5 mcg twice daily within 60 minutes prior to meals. May increase to 10 mcg after one month.• Lixisenatide: Start 10 mcg qd for 14 days then increase to 20 mcg qd.
• GFR <15 mL/minute/1.73 m²: Not recommended.
7
When and how to initiate SGLT‐2i
[1] Diabetes Care 2018; 41 (suppl 1): S73. [2] Endocrine Practice 2018; 24: 91
SGLT‐2i
Reasons to consider this group
• Reduction of hemoglobin A1c (intermediate potency)• No hypoglycemia (except if added to SU/insulin)• Weight loss• Cardiovascular benefit (empagliflozin and canagliflozin)
Drug‐specific and patient factors to consider
• Dehydration and orthostatic hypotension• Genital infections• Increased bone fracture• Risk for amputation with canagliflozin• Less common: euglycemic DKA and urosepsis• Relatively expensive
Compound (s) • Empagliflozin: Start 10 mg once daily. May increase to 25 mg once daily• GFR <45 mL/min/1.73 m²: Use is not recommended
• Canagliflozin: Start 100 mg once daily before first meal. May increase to 300 mg once daily• GFR 45‐59 mL/min/1.73 m²: Maximum dose is 100 mg once daily• GFR <45 mL/min/1.73 m²: Use is not recommended
• Dapagliflozin: Starting 5 mg once daily. May increase to 10 mg once daily• GFR <60 mL/min/1.73 m²: Use is not recommended
• Ertugliflozin: Starting 5 mg once daily. May increase to 15 mg once daily• GFR <60 mL/min/1.73 m²: Use is not recommended
Case 4
• A 46‐year‐old man who has no previous past medical history who is seen in clinic today for a routine physical. He is asymptomatic.
• His hemoglobin A1c checked today in clinic is 11% (repeat is 11.1%).
What is the most appropriate next step in management?
ADA guideline AACE/ACE guideline
Therapy for hemoglobin A1c >9%
A1c is greater than or equal 10%, blood glucose is greater than or equal 300 mg/dL, or patient is
markedly symptomatic
Consider combination injectable therapy
American Diabetes Association Dia Care 2018;41:S73-S85
A1c is greater than 9%
Is the patient symptomatic?
NoMay consider dual or triple non‐insulin therapy
Endocrine Practice 2018; 24: 91
8
Case 5
• A 45‐years‐old Male with history of type 2 diabetes, hypertension, dyslipidemia, and coronary artery disease.
• He is taking metformin XR 500 mg as two pills twice daily, insulin glargine 120 units daily, and insulin aspart 40 units three times daily before meals.
• Weight is 100 kg. Insulin/weight is 2.4 units/kg.
• Hemoglobin A1c is 10%.
What is the next step in management?
ADA guideline
Add‐on therapy to insulin
Suboptimal glycemic control requiring large insulin doses
Adjunctive use of TZD or SGLT‐2i may help to improve control and reduce the amount of insulin
needed
American Diabetes Association Dia Care 2018;41:S73-S85
Summary
• When metformin fails, we need to evaluate ASCVD risk and consider agents with established data to reduce cardiovascular disease.
• Drugs with proven CV benefits are:• Empagliflozin and canagliflozin
• Liraglutide and semaglutide (exenatide ER had a trend but were not significant)
• Pioglitazone (however, caution while using given heart failure)
• Non‐insulin agents can be considered even with severely uncontrolled diabetes (ie hemoglobin A1c >9%).
• Non‐insulin agents can be added at almost all stages of the disease even while on insulin.
9
Questions?• A Quote from Egypt
A difference of opinion does not spoil relations
• A Quote by Aristotle
The more you know, the more you know you don’t know